NPM1 and acute myeloid leukemia: Consequently, NPM1-mutated, FLT3-ITD-negative AML is classified as a favorable-risk group in the European LeukemiaNet (ELN) guidelines, whereas FLT3-ITD positivity places patients in an intermediate- or adverse-risk category depending on the allelic ratio and co-occurring mutations [159].